ContraVir Pharmaceuticals, Inc. Email Format

Biotechnology ResearchNew Jersey, United States11-50 Employees

ContraVir Pharmaceuticals, Inc. is a biotechnology company based in Edison, New Jersey, focused on the development and commercialization of targeted antiviral therapies. Its research concentrates on hepatitis B virus (HBV), pursuing two novel compounds with complementary mechanisms to address HBV infection, and a separate nucleoside analogue prodrug in a later-stage trial for herpes zoster. The company aims to offer therapies that could provide effective antiviral activity while potentially reducing certain long-term adverse effects; its pipeline includes TXL, an analog of tenofovir in Phase 2a, and CRV431, a next-generation cyclophilin inhibitor, alongside Valnivudine, which is in Phase 3 for shingles treatment and has shown potential to mitigate shingles-associated pain in prior studies. As a smaller biopharmaceutical entity, ContraVir operates within the biotech research sector, seeking to advance therapies through clinical development aimed at addressing unmet medical needs in viral diseases. A recent corporate development noted is leadership changes in 2018, including appointments affecting the company’s executive leadership and governance.

Sign up for free to view info

Company overview Employee directory